

**Ref:** EPL/CS/SE/0024/2024**Date:** November 07, 2024

To,

<b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051  <b>Script Symbol: EMCURE</b>	<b>BSE Limited</b> P J Towers, Dalal Street, Mumbai - 400 001  <b>Scrip Code/Symbol: 544210/ EMCURE</b>
--	--

Dear Sir/Madam,

**Subject: Statement of deviation(s) or variation(s) of funds under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter ended September 30, 2024**

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of proceeds raised through Initial Public Offer (IPO) for the quarter ended September 30, 2024.

We hereby confirm that there has been no deviation(s) or variation(s) in the utilization of proceeds of IPO for the abovementioned period as mentioned in the objects stated in the Prospectus dated July 05, 2024.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board at their respective meetings held today i.e. on November 07, 2024.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

**Chetan Sharma**  
**Company Secretary & Compliance Officer**  
**Membership Number: F8352**

*Encl: As above***Emcure Pharmaceuticals Limited****Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

**Statement of deviation(s) or variation(s) in utilization of proceeds raised through IPO, for the quarter ended September 30, 2024**

[under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

<b>Name of listed entity</b>	Emcure Pharmaceuticals Limited
<b>Mode of Fund Raising</b>	Public Issues
<b>Date of Raising Funds</b>	July 08, 2024
<b>Amount Raised</b>	Rs. 800 Crore
<b>Report filed for Quarter ended</b>	September 30, 2024
<b>Monitoring Agency</b>	Applicable
<b>Monitoring Agency Name, if applicable</b>	CARE Ratings Limited
<b>Is there a Deviation / Variation in use of funds raised</b>	No
<b>If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders</b>	Not applicable
<b>If Yes, Date of shareholder Approval</b>	Not applicable
<b>Explanation for the Deviation / Variation</b>	Not applicable
<b>Comments of the Audit Committee after review</b>	No comments
<b>Comments of the auditors, if any</b>	No comments

Objects for which funds have been raised and where there has been a deviation, in the following table						
Original Object	Modified Object, if any	Original Allocation (Rs. in Crores)	Modified allocation, if any	Funds Utilized till September 30, 2024 (Rs. in Crores)	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
Repayment and/or prepayment of all or a portion of certain outstanding borrowings availed by the Company	None	600.00	0	600.00	0	None
General corporate purposes	None	158.86	0	159.04	0	The main reason for increase in GCP spends is the interest income on fixed deposit received of Rs. 0.18 Crore

**Emcure Pharmaceuticals Limited**

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251

# Emcure

*Deviation or variation could mean:*

- (a) Deviation in the objects or purposes for which the funds have been raised or*
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or*
- (c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc*

**For **Emcure Pharmaceuticals Limited****

**Chetan Sharma**  
**Company Secretary & Compliance Officer**  
**Membership Number: F8352**

## **Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251